Johnson & Johnson (NYSE: JNJ) has officially closed out what CEO Joaquin Duato described as a “catapult year,” reporting robust financial results for the fourth quarter and full-year 2025. Driven by a surge in oncology sales and strategic acquisitions, the healthcare giant is now positioning itself to exceed $100 billion in annual revenue for the first time in 2026.
Financial Highlights: A Year of Accelerated Growth
For the full year 2025, Johnson & Johnson reported total sales of $94.2 billion, a 6.0% increase over 2024. The company’s net earnings saw a dramatic surge, nearly doubling to $26.8 billion, while reported earnings per share (EPS) reached $11.03.
Q4 2025 Performance:
- Reported Sales: $24.6 billion (up 9.1% YoY).
- Adjusted EPS: $2.46 (up 20.6% YoY), which includes a $0.10 impact from the acquisition of Halda Therapeutics.
- Net Earnings: $5.1 billion, representing a 49.1% increase compared to Q4 2024.
Segment Performance
Innovative Medicine (formerly Janssen)
The segment delivered $15.76 billion in Q4 sales, a 10% reported increase. Growth was heavily supported by its oncology portfolio:
- Oncology Drivers: Blockbuster drugs DARZALEX and CARVYKTI continued to see strong adoption.
- Immunology: Growth in TREMFYA helped offset a significant decline in STELARA sales, which faced a 1,040 basis point headwind due to biosimilar competition and pricing pressures.
- Neuroscience: SPRAVATO and the newly approved CAPLYTA (for major depressive disorder) contributed to a 19.1% operational growth in this sub-segment.
MedTech
The MedTech division reported $8.8 billion in Q4 sales, up 7.5%.
- Strategic Focus: The company is aggressively shifting its MedTech portfolio toward higher-growth areas like cardiovascular, surgery, and vision.
- Innovation: A major milestone was the submission of the OTTAVA Robotic Surgical System to the FDA, signaling J&J’s intent to compete more directly in the digital surgery space.
Read More: Johnson & Johnson Raises 2025 Sales Outlook on Strong Q3 Performance
Strategic Transformation: The DePuy Synthes Spinoff
In a move to further streamline operations, Johnson & Johnson confirmed its intent to separate its Orthopaedics business (DePuy Synthes) into a standalone company. This separation, expected to take 18–24 months, will allow the core J&J business to focus on high-margin innovative medicines and advanced MedTech sectors like robotics. Namal Nawana has been appointed to lead DePuy Synthes through this transition.
AstraZeneca’s Enhertu EU Approval: Enhertu Plus Pertuzumab Cleared as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer, marking AstraZeneca and Daiichi Sankyo's first new EU […]
2026 Outlook: The $100 Billion Goal
Looking ahead, Johnson & Johnson issued optimistic guidance for 2026, forecasting reported sales between $100.0 billion and $101.0 billion.
- 2026 Sales Midpoint: $100.5 billion (6.7% growth).
- 2026 Adjusted EPS Midpoint: $11.53 (6.9% growth).
Market Reaction
Despite the record revenue and strong guidance, J&J shares saw a slight pre-market dip of approximately 2%, as investors weighed the $0.07 miss on adjusted EPS consensus estimates (impacted by acquisition costs) and the ongoing transition of the STELARA franchise. However, analysts remain generally positive on the company’s long-term roadmap and aggressive pipeline expansion.
Last Modified:
